Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23392024 | 0.92 | IRAK4 (0.41) | IRAK4IRAK1TGFBR1CYP2D6TGFBR2 | |
| SCHEMBL30155953 | 0.88 | MELK (0.36) | TGFBR1MTORCYP2D6TGFBR2MAP3K20 | |
| SCHEMBL23389758 | 0.84 | TGFBR1 (0.36) | IRAK4IRAK1TGFBR1MTORCYP2D6 | |
| SCHEMBL29967691 | 0.84 | TGFBR1 (0.36) | IRAK4IRAK1TGFBR1MTORCYP2D6 | |
| SCHEMBL25085211 | 0.81 | TGFBR1 (0.40) | TGFBR1MTORMAPK14METPIK3CA | |
| SCHEMBL23392175 | 0.80 | TGFBR1 (0.45) | TGFBR1MTORMAPK14MET | |
| SCHEMBL23391953 | 0.79 | TGFBR1 (0.38) | TGFBR1MTORCYP2D6TGFBR2MAP3K20 | |
| SCHEMBL23392209 | 0.78 | TGFBR1 (0.39) | TGFBR1MTORCYP2D6TGFBR2MAP3K20 | |
| SCHEMBL25084657 | 0.78 | FLT3 (0.43) | IRAK4TGFBR1MTORCYP2D6TGFBR2 | |
| SCHEMBL30156407 | 0.78 | FLT3 (0.43) | IRAK4TGFBR1MTORCYP2D6TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | claimed |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | claimed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | IRAK4 330/4885IRAK1 484/4885TGFBR1 211/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | IRAK4 330/4885IRAK1 484/4885TGFBR1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.